Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Abstract
Improving survival of patients with glioblastoma (GBM) using antiangiogenic therapy remains a challenge. In this study we show that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels. The antitumor immunomodulatory potential of this dual blockade supports clinical testing of this approach for GBM with other immunotherapeutic approaches such as checkpoint blockers.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 04, 2016
- Source ID
- 10.1073/pnas.1525360113
Entities
People
- Alona Muzikansky
- Ana Batista
- Christine Lu-emerson
- Dai Fukumura
- Dan G Duda
- Giorgio Seano
- Hiroaki Wakimoto
- Jennie W. Taylor
- Jonas Kloepper
- Jonathan W. Song
- Katharina Susek
- Kay G. Stubenrauch
- Keehoon Jung
- Lance L. Munn
- Lars Riedemann
- Lei Xu
- Matija Snuderl
- Meenal Datta
- Nathaniel D. Kirkpatrick
- Nisha Dalvie
- Oliver Krieter
- Rakesh Jain
- Robin L. Amelung
- Tracy T. Batchelor
- Vasileios Askoxylakis
- Veronica Yu
- Zohreh Amoozgar
Organizations
- Harvard Medical School
- Hoffmann-La Roche
- National Institutes of Health
- Tufts University
- United States Department of Defense